Navigation Links
Cell Therapeutics, Inc.'s Second Quarter 2008 Financial Results
Date:8/17/2008

1, 2008. Separately, the Centers for Medicare & Medicaid Services proposed to reimburse Zevalin based on the Average Sales Price methodology, which is currently used for drugs and biologicals, in 2009.

-- Completed enrollment for phase II clinical trial of brostallicin as first-line therapy in patients with newly diagnosed advanced or metastatic soft tissue sarcoma.

-- Announced that Craig Philips, most recently Vice President and General Manager of Bayer Healthcare Oncology, assumed day to day role as President of CTI with direct responsibilities for development and commercial operations.

-- Repaid balance of approximately $10.7 million for 2008 Convertible Notes leaving Company with no debt maturing before Q3 2010 and established equity line of credit for the sale of up to $12 million of common stock over time.

Total operating expenses increased to $28.7 million for the quarter ended June 30, 2008 compared to $24.3 million for the same period in 2007 mainly as a result of increased expenses related to support expansion of Zevalin sales and marketing efforts and legal expenses. Net loss attributable to common shareholders for the quarter ended June 30, 2008, totaled $59.3 million ($0.52 per share), which included $25.6 million in make-whole interest expense due to the conversion of the 9% and 13.5% convertibles notes into common stock that resulted in a decrease of approximately $39.6 million in debt, compared to $27.9 million ($0.65 per share) for the comparable period in 2007. The decrease in net loss per share is due to an increase in the number of shares outstanding.

The Company had approximately $12.4 million in cash and cash equivalents, securities available-for-sale, and interest receivable as of June 30, 2008. This does not include $26.9 million in restricted cash held in escrow for future make-whole and interest payments on our 9%, 13.5% and 15% convertible notes as well as net cash proceeds of approximately $4.5 million
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage biopharmaceutical company ... at three investor conferences: , Wednesday, September 9 ... New York at the New York ... at the BioCentury NewsMakers Conference in New York ... , Thursday, September 17 at 9:30 AM at the ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... managed with the use of special anti-vascular endothelial growth factor agents given by ... patients, currently does not have a scientific protocol for the many millions diagnosed ...
(Date:9/2/2015)... Mass. (PRWEB) , ... September 02, 2015 , ... ... includes development of botanical and plant-derived compounds. BCC Research reveals in its ... past 2020 because this market defines the category and generates the most market ...
(Date:9/2/2015)... , September 2, 2015 ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, announced today that presentations highlighting ... will be delivered at the Ophthalmology Futures European ... Society of Cataract & Refractive Surgeons ("ESCRS"), both ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... Inc. (Sparta),the maker of TrackWise(R), and the market ... that its TrackWise solution has,been chosen by Protherics ... manufacturing and marketing of specialized products for,critical care ... handling,processes. TrackWise provides organizations with a single, ...
... Oct. 24 Human Genome,Sciences, Inc. (Nasdaq: HGSI ... to discuss its financial results for the quarter ended,September ... on Thursday,November 1, 2007. (Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO ) ... management and will be,held on Thursday, November 1, 2007, ...
... Call on Thursday, October 25, 2007 at ... ... Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical company focused ... the treatment of life-threatening,diseases, including diabetes and cancer, today announced its ...
Cached Biology Technology:Protherics UK Ltd. Chooses TrackWise for Corrective Action and Preventive Action (CAPA) Management 2Human Genome Sciences To Sponsor Conference Call To Discuss Third Quarter 2007 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 4Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 5Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results 6
(Date:8/20/2015)... SANTA CLARA, Calif. , Aug. 20, 2015 ... based company focused on improving the user experience ... voice and vision technologies, today announced that its ... and voice biometric authentication software to be ... Alliance tested TrulySecure for compliance with the FIDO ...
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... 16, 2011 A new episode in the American ... podcast series spins a real-life tale in which spider ... the use of gene therapy in everyday medicine. ... explains in non-technical language that gene therapy involves the ...
... KAN. -- A Kansas State University research group is ... young children and prevent childhood obesity. The researchers ... head -- have developed a program called HOP,N Home, ... Nutrition at Home. The researchers have been working on ...
... headed by Prof. Johanna Ivaska (University of Turku and VTT ... of Turku and the National Institute for Health and Welfare) ... Published in a leading journal, the study concludes ... and of lung and prostate cancer cells. It is likely ...
Cached Biology News:New American Chemical Society podcast: Genetically-engineered spider silk for gene therapy 2Research aims to prevent obesity by reaching parents, young children through child care 2Research aims to prevent obesity by reaching parents, young children through child care 3
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Phosphatidylinositol transfer protein beta isoform (PtdIns transfer protein beta) (PtdInsTP) (PI-TP-beta). [Source:Uniprot/SWISSPROT;Acc:P48739] Antigen: Recombinant Protein Epitope Signature Tag...
Desmosomal Protein Immunogen: Full length, native protein purified from human epidermal keratins. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Biology Products: